Comparison of isoniazid monoresistant tuberculosis with drug-Susceptible tuberculosis and multidrug-Resistant tuberculosis

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 7, 2011, Pages 863-867

  Fox, L ^a,b   Kramer, M R ^a   Haim, I ^b   Priess, R ^b   Metvachuk, A ^c,d   Shitrit, D ^b,c,d  

^a RABIN MEDICAL CENTER   (Israel)

^b Tuberculosis Center   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIRECTLY OBSERVED THERAPY; DRUG TREATMENT FAILURE; FEMALE; HEMOPTYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; WEIGHT REDUCTION;

ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; EMIGRANTS AND IMMIGRANTS; FEMALE; HIV INFECTIONS; HUMANS; ISONIAZID; ISRAEL; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RISK FACTORS; SMOKING; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 80051664373     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1167-4     Document Type: Article

References (12)

1. Centers for Disease Control and Prevention (CDC) (1992) National action plan to combat multidrug-resistant tuberculosis. MMWR Recomm Rep 41(RR-11):5-48
2. Centers for Disease Control and Prevention (CDC) (2006) Reported tuberculosis in the United States, 2005. U.S. Department of Health and Human Services, Atlanta, GA
3. Cattamanchi A, Dantes RB, Metcalfe JZ et al (2009) Clinical characteristics and treatment outcomes of patients with isoniazidmonoresistant tuberculosis. Clin Infect Dis 48(2):179-185
4. Hoopes AJ, Kammerer JS, Harrington TA et al (2008) Isoniazidmonoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 168(18):1984-1992
5. American Thoracic Society; CDC; Infectious Diseases Society of America (2003) Treatment of tuberculosis [published correction appears in MMWR Recomm Rep. 2005;53(51):1203]. MMWR Recomm Rep 52(RR-11):1-77
6. Moore M, Onorato IM, McCray E et al (1997) Trends in drug-resistant tuberculosis in the United States, 1993-1996. JAMA 278:833-837 (Pubitemid 27383373)
7. Forssbohm M, Loddenkemper R, Rieder HL (2003) Isoniazid resistance among tuberculosis patients by birth cohort in Germany. Int J Tuberc Lung Dis 7:973-979 (Pubitemid 37237061)
8. Sterling TR, Bethel J, Goldberg S et al; Tuberculosis Epidemiologic Studies Consortium (2006) The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 173:927-931
9. Centers for Disease Control and Prevention (CDC), National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (2006) Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association. MMWR Recomm Rep 55 (RR-9):1-44
10. Escalante P, Graviss EA, Griffith DE et al (2001) Treatment of isoniazid-resistant tuberculosis in southeastern Texas. Chest 119:1730-1736 (Pubitemid 32744929)
11. Institute of Medicine (2000) Ending neglect: the elimination of tuberculosis in the United States. National Academy Press, Washington, DC
12. Scior T, Meneses Morales I, Garcés Eisele SJ et al (2002) Antitubercular isoniazid and drug resistance of Mycobacterium tuberculosis-a review. Arch Pharm (Weinheim) 335:511-525 (Pubitemid 36314140)